New Hope Network is part of the divisionName Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Glanbia Granted U.S. Patent for Prolibra Whey Ingredient

Glanbia Nutritionals has announced the granting of a US patent for Prolibra (1). Prolibra is a whey-derived ingredient including proprietary whey peptides. It is clinically proven to significantly decrease fat mass while maintaining lean body mass in combination with a hypocaloric diet. Prolibra also helps reduce post-prandial glycemic response, an acknowledged dietary approach for achieving healthy weight loss.

Two independent trials have demonstrated clinical significance using Prolibra to reduce body fat while retaining lean muscle mass. In the first clinical study, total body fat mass was significantly reduced in the Prolibra group versus a placebo. On average, the experimental group experienced a 5.81 percent reduction in body fat compared to the placebo group, at 2.29 percent. The second clinical study (2) established that Prolibra has a significant impact on fat loss and muscle mass retention. This 12-week double-blind placebo-controlled study showed that 79 percent of the weight loss by the Prolibra group was fat, compared with 51 percent in the control group.

In both trials, subjects saw a >5 percent reduction in overall body fat. This result has practical significance, as a five percent reduction in body fat mass has been shown to reduce the risk of obesity-related disease. The retention of lean mass is critical to maintaining basal metabolic rate, strength, agility and overall health—and aids in controlling the effect of yo-yo dieting, a negative outcome of traditional diets.

A third study (3) demonstrated that Prolibra considerably reduces postprandial glycemia, with participants experiencing a statistically significant reduction of up to 37.8 glycemic index (GI) units after consumption of Prolibra in a liquid glucose beverage. Consuming foods with a low GI is one dietary approach for achieving healthy weight loss and may aid weight loss through the control of appetite, the delay of hunger, and the reduction of insulin levels and insulin resistance.

Sharon Rokosh, business development manager at Glanbia Nutritionals, said: "With overweight and obesity rates still a major concern in the developed world, weight management products can provide a key way to optimize a healthy diet. The awarding of the patent, coupled with the clinical substantiation for Prolibra, reinforces the significance of this unique weight loss ingredient."

Prolibra offers a clean, neutral flavour. It can be added to a wide variety of appealing consumer products, such as nutrition bars, snacks and a range of beverage applications, including dairy beverages, smoothies, fruit drinks and RTD and powdered beverages.

(1) US patent 7,790,670. Patent holder is Glanbia Nutritionals (Ireland)


(2) A whey-protein supplement increases fat loss and spares lean muscle in obese subjects: A randomized human clinical study, Nutrition & Metabolism, 2008.

(3) Determination of Glycemic Index Lowering Potential of Prolibra, a report from Glycemic Index Laboratories.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.